Ultimate
Predictability

genOway offers preclinical models and solutions to bio-pharmaceutical and academic researchers for ultimate predictability.
Our hGLP-1R mouse model supports the assessment of human-specific GLP-1R agonists for treating type 2 diabetes and obesity
Learn more
Our Pan hCD3 mouse model enables the efficacy assessment of TCEs and chemotherapy combination treatments
Learn more
Discover how our hFcγR mouse model can help you achieve a translatable assessment of your therapeutic antibodies
Learn more

Ensuring the ultimate predictability of your research

At genOway, we recognize the crucial role that preclinical research plays in the success of new therapies in clinical settings. Our team of experts brings together decades of experience in designing genetically modified models and a profound understanding of biological physiology to provide unmatched preclinical solutions.

Our collaborative approach, rooted in a deep understanding of your specific needs and complemented by our expertise, strives to define the best solution to predict the success of your research. Join us on a journey of scientific advancement for the benefit of human health.

  • 28
    countries worldwide
  • 380
    academic institutions
  • 13
    EU projects
  • 170
    Life Sciences companies
  • 17
    of the Top 20 pharma

Catalog models

Explore our comprehensive catalog of preclinical models, featuring genetically modified mice, rats, and cell lines. All our models were designed and validated with the highest standards of excellence to ensure the ultimate predictability of your research.

Learn more

Customized models

Explore our service for creating genetically modified mouse, rat, and cell line models perfectly adapted to answer your scientific questions. With an in-depth understanding of your needs, our team of scientific experts, committed to your side, will accompany you throughout this journey.

Learn more
Our latest resources and publications
Posters
Scientific Articles
Commentaries
Case studies
(Teva Pharmaceuticals) Preclinical in vivo characterization of the anti-tumor activity of a non-blocking PD-1 antibody fused to attenuated IL-2

Anti-tumor immunotherapy

Nov 2024
(Anaveon) ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells

Efficacy assessment with hPD-1

Nov 2024
(Anaveon) ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4 + and CD8 + tumor specific T cells by acting in the tumor microenvironment and draining lymph nodes

Anti-tumor efficacy with hPD-1

Nov 2024
Show all posters
GalNT2-mediated O-glycosylation affects pancreas development and function in mice

Sci Rep

2024
NK2R control of energy expenditure and feeding to treat metabolic diseases

Nature

2024
PAR2 on oral cancer cells and nociceptors contributes to oral cancer pain that can be relieved by nanoparticle-encapsulated AZ3451

Biomaterials

2024
Show all scientific articles
A radiolabeled VISTA antibody for imaging VISTA expression

hVISTA - antibodies & PET imaging

7 min read
-
Oct 2024
New CD4-specific minibodies to predict cancer treatment outcomes

CD4 for cancer treatment outcomes

5 min read
-
Oct 2024
Development of a new antibody-drug conjugate against CD71, INA03, for the treatment of leukemia

TFRC for anti-cancer therapies

8 min read
-
Jul 2024
Show all commentaries
Show all case studies